VIEW WEBSITE >>
1 known investors
Leucid Bio develops a proprietary Lateral CAR platform for chimeric antigen receptor T-cell (CAR-T) therapies in oncology. The platform is designed to enhance T-cell potency and reduce toxicity compared to previous-generation CAR-T treatments.
AI & Machine LearningBiotechMedical Devices
Founders & leadership
JM
John Maher